

For Immediate Release: February 10, 2022

Contact Information:

Jill Hronek, Director of [SLAS Discovery](#)

Oak Brook, IL – In 2022, *SLAS Discovery* completed its first year of open access publishing, introduced Protocols articles, and increased its impact factor to 3.341.

The *SLAS Discovery* Editor's Top 10 for 2022 highlights articles that contribute to the journal's goals in educating and encouraging scientific collaboration by addressing the common and topical interests in drug discovery and the life sciences. These top 10 articles include new COVID-19 drug discovery efforts using high-throughput screening approaches; proving the necessity for developing new ways to represent diseased patient potential treatments for diseases without a known cure, such as autism spectrum disorder and ob

SLAS Discovery Editor-in-Chief Robert M. Campbell, Ph.D. (Redona Therapeutics), acknowledges the authors, editors and reviewers for their time and dedication in delivering fascinating research to *SLAS Discovery* and its readers. The *SLAS Discovery* [Editor's Top 10 editorial](#) is published in V

Dias, Romenia Ramos Domingues, Murilo de Carvalho, Matheus de Castro Fonseca, Vanessa Kiraly Thomaz Rodrigues, Adriana Franco Paes Leme, Ana Carolina Migliorini Figueira (*SLAS Discovery* **2022**, *27*, 167-174)

[Development of high-throughput lacrimal gland organoid platforms for drug discovery in dry eye disease](#)

By Teerapat Rodboon, Supansa Yodmuang, Risa Chaisuparat, Joao N. Ferreira (*SLAS Discovery* **2022**, *27*, 151-158)

[Multifunctional profiling of triple-negative breast cancer patient-derived tumoroids for disease modeling](#)

By Evan F. Cromwell, Oksana Sirenko, Ekaterina Nikolov, Matthew Hammer, Courtney K. Brock, Margarite D. Matossian, Madlin S. Alzoubi, Bridgette M. Collins-Burow, Matthew E. Burow (*SLAS Discovery* **2022**, *27*, 191-200)

[A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry](#)

By Miao Xu, Manisha Pradhan, Kirill Gorshkov, Jennifer D. Petersen, Min Shen, Hui Guo, Wei Zhu, Carleen Klumpp-Thomas, Sam Michael, Misha Itkin, Zina Itkin, Marco R. Straus, Joshua Zimmerberg, Wei Zheng, Gary R. Whittaker, Catherine Z. Chen (*SLAS Discovery* **2022**, *27*, 86-94)

[Identification of potent small molecule inhibitors of SARS-CoV-2 entry](#)

By Sonia Mediouni, Huihui Mou, Yuka Otsuka, Joseph Anthony Jablonski, Robert Scott Adcock, Lalit Batra, Dong-Hoon Chung, Christopher Rood, Ian Mitchell S. de Vera, Ronald Rahaim Jr., Sultan Ullah, Xuerong Yu, Yulia A. Getmanenko, Nicole M. Kennedy, Chao Wang, Tu-Trinh Nguyen, Mitchell Hull, Emily Chen, Thomas D. Bannister, Pierre Baillargeon, Louis Scampavia, Michael Farzan, Susana T. Valente, Timothy P. Spicer (*SLAS Discovery* **2022**, *27*, 8-19)

[Screening for modulators of autism spectrum disorder using induced human neurons](#)

By Sumitha Rajendra Rao, Ana Kostic, Pierre Baillargeon, Virneliz Fernandez-Vega, Mitzy Rios de Anda, Kelty Fletcher, Justin Shumate, Louis Scampavia, Joseph D. Buxbaum, Timothy P. Spicer (*SLAS Discovery* **2022**, *27*, 128-139)

[Adipocyte-based high throughput screening for anti-obesity drug discovery: current status and future perspectives](#)

By Leo Tsui (*SLAS Discovery* **2022**, *27*, 375-383)

SLAS Discovery reports how scientists develop and use novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. The journal focuses on drug discovery sciences with a strong record of scientific rigor and impact, reporting on research that:

Enables and improves target validation

